Overview

A Study of LY2828360 in Patients With Osteoarthritic Knee Pain

Status:
Completed
Trial end date:
2011-09-01
Target enrollment:
Participant gender:
Summary
To investigate the safety, efficacy and pharmacokinetics of single daily oral dose of LY2828360 in male and female subjects with osteoarthritic knee pain
Phase:
Phase 2
Details
Lead Sponsor:
Eli Lilly and Company